期刊文献+

Bcl-2抑制剂S1诱导人卵巢癌细胞凋亡及其机制的研究 被引量:3

Research of mechanism that inhibitor of Bcl-2 S1 induce SKOV3 cell apoptosis
下载PDF
导出
摘要 目的:以人卵巢癌细胞SKOV3为研究对象,探讨Bcl-2抑制剂S1诱导人卵巢癌细胞凋亡的机制。方法:通过MTT法检测S1作用下卵巢癌细胞的生存率;S1 10μmol/L作用不同时间,流式细胞术检测细胞凋亡率;Western Blot检测凋亡相关蛋白Mcl-1的变化。结果:与对照组相比S1能明显抑制SKOV3的生存率;流式细胞术结果显示,S1引起SKOV3细胞凋亡明显升高;蛋白水平检测S1作用8 h能明显抑制SKOV3细胞Mcl-1蛋白表达。结论:S1可能通过抑制Mcl-1蛋白诱导人卵巢癌细胞凋亡。 Objective To investigate the apoptosis mechanism induced by micromolecule compound S1 in human ovarian cancer cells SKOV3. Method Cell viability was detected by MTT to S1 in ovarian cancer cells SKOV3 ; The apoptosis rate of SKOV3 cells was deter- mined by Flow Cytometry analysis; Western blotting was used to analyze the expression of the protein of Mcl - 1. Results MTr assay indicated that compared with control group,S1 can decrease the cell viability of SKOV3 cells. It significantly activated the apoptosis in SKOV3 ceils measured by Flow Cytometry analysis treated with S1. Western blotting showed the result that apoptosis - relative protein Mcl - 1 was inhibited by S1 in human Ovarian cancer cells. Condusion The main mechanisms that S1 induce SKOV3 cell apoptosis through the way that inhibit Mcl - 1 protein.
出处 《吉林医学》 CAS 2012年第13期2693-2695,共3页 Jilin Medical Journal
基金 吉林大学"大学生创新性实验计划"项目(项目编号:2011A71126) 吉林省科技厅资助项目(项目编号:200705373)
关键词 人卵巢癌细胞 S1 MCL-1 凋亡 Ovarian cancer cells S1 Mcl - 1 Apoptosis
  • 相关文献

参考文献8

  • 1Mesner PJ, Budihardjo II, Kaufmann SH. Chemotherapy - induced apoptosis [ J ]. Adv Pharmacol, 1997,41 : 461.
  • 2Simonian PL, G611ot DA. M, Nunz G. Bcl - 2 anb bcl - XL can differentially block chemotherapy - induced cell death [ J]. Blood, 1997,90 (3) : 1208.
  • 3Gross A,James M. McDonnell,Stanley J. Korsmeyer. BCL -2 family members and the mitochondria in apoptosis [ J ]. Genes Dev, 1999,13 : 1899.
  • 4马强.Bcl-2基因家族与肿瘤多药耐药性的研究[J].医学综述,2002,8(6):324-326. 被引量:3
  • 5Kang MH,Reynolds CP. Bcl -2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy [ J ]. Clin Cancer Res ,2009,15 : 1 t26.
  • 6Zhang Z,Wu G,Gao J,et al. Inclusion complex of a Bc1-2 inhibitor with cyclodextrin : characterization, cellular accumula- tion,and in vivo antitumor activity [ J] . Mol Pharm, 2010, 7: 1348.
  • 7Neal B. Blatt, Anthony E. Boitano, Costas A. Lyssiotis, et al. Bz- 423 Superoxide Signals B Cell Apoptosis via Mcl - 1, Bak,and Bax[J]. Biochem Pharmacol,2009,78(8) : 966.
  • 8Luke R. E. Harrison, Dimitra Micha, Martin Brandenburg, et al. Hypoxic human cancer cells are sensitized to BH - 3 mimetic induced apoptosis via downregulation of the Bcl - 2 protein bld - l[J]. J Clin Invest,2011,121(3) : 1075.

二级参考文献16

  • 1Sikic BI. Pharmacologie approaches to reversing multidrug resistance[J]. Semin Hematol, 1997,34[4 Suppl 5] :40-47.
  • 2Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells[J]. Biochemistry, Most ,2000,65( 1 ) :95-106.
  • 3Minn AJ, Velez P,Schendel SL, et al. Bel-x(L) forms an ion channel in synthetic lipid membranes[J]. Nature, 1997,385(6614):353-357.
  • 4Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy induced apoptosis in a human leukemia cell line [ J ]. Blood, 1993,81 ( 1 ) : 151-157.
  • 5Kamesaki S, Kamesaki H, Jorgensen TJ, et al. Bcl-2 protein inhibits etopside induced apoptosis through its effects on events subsequent to topoisomerase induced DNA strand breaks and their repair[ J]. Cancer Res, 1993,53(18) :4251-4256.
  • 6Fu D, Shi Z, Wang Y. Bcl-2 plays a key role instead of mdrl in the resistance to hexadecylphosphocholine in human epidermoid tumor cell line KB[J]. Cancer Lett, 1999, 142(2) : 147-153.
  • 7Campos L, Rouault JP, Sabido O, et al. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy[ J]. Blood, 1993,81 ( 11 ) : 3091-3096.
  • 8Webb A, Cunningham D, Cotter F, et al. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma [ J ]. Lancet, 1997,349 ( 9059 ) :1137-1141.
  • 9Huang Y, Ibrado AM, Reed JC, et al. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells[ J]. Leukemia, 1997,11(2) :253-257.
  • 10Minn AJ, Rudin CM, Boise LH, et al. Expression of Bcl-xL can confer a multidrug resistance phenotype[ J]. Blood, 1995,86(5 ) : 1903-1910.

共引文献2

同被引文献46

  • 1丁江华,张荣艳,彭燕.慢性粒细胞性白血病P-gp和Bcl-2表达及与病情进展的关系[J].江西医学院学报,2004,44(6):13-15. 被引量:1
  • 2金礼吉,张志超,王媛媛,魏美娇,徐芹.一个全新的有机小分子Bcl-2蛋白抑制剂[J].中国科学(C辑),2007,37(4):416-421. 被引量:1
  • 3Marzo I, Naval J. Bcl-2 family members as molecular targets in cancer therapy [J]. Biochem Pharmacol, 2008, 76 (8) : 939-946.
  • 4Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer [J]. Cell Mol Life Sci, 2008, 66 (8) : 1326-1336.
  • 5Yang T, Kozopas KM, Craig RW. The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those ofBcl-2 [J]. J Cell Biol, 1995, 128(6): 1173-1184.
  • 6Thomas LW, Lam C, Edwards SW. Mcl-1; the molecular regulation of protein function [J]. FEBSLett, 2010, 584 (14) :2981-2989.
  • 7Jamil S, Sobouti R, Hojabrpour P, et al. A proteolytic fragment of Mcl-1 exhibits nuclear localization and regulates cell growth by interaction with Cdkl [J]. Biochem J, 2005, 387 (Pt 3) : 659-667.
  • 8Gandhi L, Camidge DR, Ribeiro de Oliveira M, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors [J]. J Clin Oncol, 2011, 29 (7) : 909-916.
  • 9Baggstrom MQ, Qi Y, Koczywas M, et al. A phase II studyof AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer [J]. J Thorac Oncol, 2011, 6(10): 1757-1760.
  • 10Keuling AM, Felton KE, Parker AA, et al. RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway [J]. PLoS One, 2009, 4(8): e6651.

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部